Good morning, everyone, and welcome to another busy day. You made it this far this week, so why not continue, yes? While you ponder the possibilities, we will celebrate a gorgeous morning with some needed cups of stimulation. After the heat and humidity of the past few days, a sparkling sun and coooool breeze are quite welcome. And of course, we are happy to pass along the latest menu of tidbits to get you started on your way. Hope you have a smashing day, and do stay in touch. We accept documents and tips. …

Gilead Sciences (GILD) plans to make more of its experimental remdesivir treatment available for Europe as of this coming autumn and will decide how much each country gets based on the rate of infection, Reuters writes. Bettina Bauer, managing director of Gilead in Germany, told WirtschaftsWoche that the company can increase its worldwide monthly production from currently 190,000 treatment cycles to 2 million treatment cycles in December. Bauer said she was in talks with the German government about increasing supply.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy